Research programme: sepsis therapy - Ascentia Biomedical/University of Washington
Latest Information Update: 27 Mar 2008
At a glance
- Originator University of Washington
- Developer Ascentia Biomedical Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 15 Aug 2005 Preclinical trials in Sepsis in USA (unspecified route)